Can GLP-1 Medications Cause Blindness? What the Evidence Actually Shows

Direct Answer

GLP-1 medications, particularly semaglutide, don't cause blindness directly, but several real, published studies have found an association with NAION (non-arteritic anterior ischemic optic neuropathy), a rare condition affecting blood flow to the optic nerve that can cause sudden, often permanent vision loss in one eye. The evidence on this is genuinely mixed, not settled, and the most recent, largest analysis found no increased risk at all.

The Real Evidence, Both Directions

A study published in JAMA Ophthalmology in July 2024 found a real, notable difference: a 6.7% cumulative incidence of NAION over 36 months among semaglutide users, versus 0.8% in a comparison group. Several other observational studies since have found similar signals. However, a large, rigorously conducted pooled analysis of over 119,000 patient-years of clinical trial data, published in April 2026, found no imbalance in ophthalmologist-confirmed NAION cases between GLP-1 medication and placebo groups. This is a real, genuine scientific disagreement, not a settled question, and it's actively still being studied.

Real Regulatory Action

The European Medicines Agency began a formal safety review of semaglutide and NAION on January 17, 2025. That review's 2025 findings estimated that, if the association is real, NAION may affect up to 1 in 10,000 people taking the medication, a real, low absolute risk even under the more cautious interpretation of the evidence.

What Medical Experts Actually Recommend

A real, joint consensus statement from NANOS (the North American Neuro-Ophthalmology Society) and the American Academy of Ophthalmology states plainly: anyone taking a GLP-1 medication who experiences sudden vision loss should get immediate evaluation by an ophthalmologist. Whether to start, continue, or stop GLP-1 treatment after a NAION diagnosis is a shared decision between patient and provider, based on individual risk factors, not a one-size-fits-all answer.

Bottom Line

This is a real, actively-studied safety question with genuinely mixed evidence, not a confirmed, settled risk. The one clear, actionable point across every source: sudden vision changes while on a GLP-1 medication warrant immediate medical attention, not a wait-and-see approach.

References

• Hathaway et al., JAMA Ophthalmology (July 2024)
• NANOS and American Academy of Ophthalmology Consensus Statement on GLP-1 RAs and NAION
• European Medicines Agency, semaglutide/NAION safety review (2025)
• Vilsbøll et al., British Journal of Ophthalmology, pooled clinical trial analysis (April 2026)

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Get Started

Explore the GLP-1 Tracker knowledge base for accurate, sourced information on every GLP-1 medication.

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This article is for general informational purposes and is not medical advice. If you experience sudden vision changes, seek immediate medical attention.